Development of a Novel Blood‐Based Brain‐Derived Tau Biomarker for Alzheimer's Disease and Brain Injury

Abstract

Background: Brain‐derived tau (BD‐tau) is an emerging blood‐based biomarker for neurodegeneration associated with Alzheimer's disease (AD). Currently, there are limited BD‐tau assays available for research and clinical use. The only existing commercial assay is still undergoing validation, limiting its acceptance among researchers.

The paper